A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Status:
Terminated
Trial end date:
2017-01-02
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm, phase II study. The study population is adult patients
with asymptomatic recurrent ovarian cancer who have an elevation in their CA-125 level.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc